Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harmony Biosciences Holdings (HRMY) Inventory (2019 - 2025)

Historic Inventory for Harmony Biosciences Holdings (HRMY) over the last 7 years, with Q3 2025 value amounting to $7.0 million.

  • Harmony Biosciences Holdings' Inventory rose 189.44% to $7.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.0 million, marking a year-over-year increase of 189.44%. This contributed to the annual value of $7.2 million for FY2024, which is 3421.59% up from last year.
  • Per Harmony Biosciences Holdings' latest filing, its Inventory stood at $7.0 million for Q3 2025, which was up 189.44% from $6.3 million recorded in Q2 2025.
  • In the past 5 years, Harmony Biosciences Holdings' Inventory ranged from a high of $7.2 million in Q4 2024 and a low of $4.5 million during Q3 2022
  • Moreover, its 5-year median value for Inventory was $5.2 million (2021), whereas its average is $5.5 million.
  • In the last 5 years, Harmony Biosciences Holdings' Inventory soared by 12168.22% in 2021 and then tumbled by 1336.51% in 2022.
  • Quarter analysis of 5 years shows Harmony Biosciences Holdings' Inventory stood at $4.9 million in 2021, then grew by 0.72% to $4.9 million in 2022, then increased by 9.09% to $5.4 million in 2023, then soared by 34.22% to $7.2 million in 2024, then fell by 2.11% to $7.0 million in 2025.
  • Its Inventory stands at $7.0 million for Q3 2025, versus $6.3 million for Q2 2025 and $6.5 million for Q1 2025.